MediWound Ltd.
NASDAQ Global MarketTotal Valuation
MediWound Ltd. carries a market capitalization of 149.47M, placing it among publicly traded companies globally. Its enterprise value stands at 199.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 149.47M |
| Enterprise Value | 199.66M |
Share Statistics
MediWound Ltd. currently has 12.85M shares outstanding.
| Shares Outstanding | 12.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 13.23 |
| PB Ratio | N/A |
| P/TBV Ratio | 4.63 |
| P/FCF Ratio | -15.45 |
| P/OCF Ratio | -10.21 |
Enterprise Valuation
| EV / Sales | 13.79 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
MediWound Ltd. maintains a current ratio of 2.41, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.62, indicating elevated leverage, while an interest coverage ratio of -3.46 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.41 |
| Quick Ratio | 0.13 |
| Debt / Equity | 19.62 |
| Debt / EBITDA | -0.31 |
| Interest Coverage | -3.46 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -35.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.79 |
Taxes
| Income Tax | 147,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
MediWound Ltd.'s stock has declined approximately -36.26679% over the past 52 weeks. The 50-day moving average sits at 16.51, while the 200-day moving average is 17.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | -36.26679% |
| 50-Day Moving Average | 16.51 |
| 200-Day Moving Average | 17.49 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, MediWound Ltd. generated 14.48M in revenue and converted that into -26.10M in net income, yielding earnings per share of -2.20. EBITDA reached -26.15M, while operating income came in at -28.03M.
| Revenue | 14.48M |
| Gross Profit | 2.84M |
| Operating Income | -28.03M |
| Pretax Income | -25.96M |
| Net Income | -26.10M |
| EBITDA | -26.15M |
| EBIT | -28.03M |
| Earnings Per Share (EPS) | -2.20 |
Balance Sheet
| Cash & Cash Equivalents | N/A |
| Total Debt | 8.13M |
| Net Debt | N/A |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 30.52M |
Cash Flow
MediWound Ltd. produced -18.76M in operating cash flow over the past twelve months. After subtracting -6.37M in capital expenditures, free cash flow totaled -25.13M - equivalent to -2.11 per share.
| Operating Cash Flow | -18.76M |
| Capital Expenditures | -6.37M |
| Free Cash Flow | -25.13M |
| FCF Per Share | -2.11 |
Margins
MediWound Ltd. operates with a gross margin of 19.61, reflecting its pricing power and cost economics. The operating margin of -193.62 and net profit margin of -180.30 provide insight into operational efficiency.
| Gross Margin | 19.61 |
| Operating Margin | -193.62 |
| Pretax Margin | -179.28 |
| Profit Margin | -180.30 |
| EBITDA Margin | -180.63 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -15.43 |
| FCF Yield | -6.47 |
Stock Splits
MediWound Ltd.'s most recent stock split took place on December 20, 2022 with a 7:1 split ratio.
| Last Split Date | 12/20/2022 |
| Split Ratio | 7:1 |
Scores
MediWound Ltd. posts an Altman Z-Score of 2.46, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.46 |